Migard (Frovatriptan)

Frovatriptan works by binding to serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This binding causes vasoconstriction of dilated intracranial arteries and blocks the release of inflammatory neuropeptides, interrupting the pain pathway that triggers migraine.

The appropriate dose of Migard is determined by a qualified prescriber based on the individual patient's clinical condition, response, and any relevant medical history. Patients should follow the prescribing information provided by their healthcare professional.

The safety of frovatriptan in pregnancy or while breastfeeding has not been definitively established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and after discussion with a healthcare provider.

To order Migard, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Migard (frovatriptan) is a long‑acting triptan, offering a slower onset but a prolonged duration of action compared with faster‑acting triptans such as sumatriptan. This profile can be advantageous for migraine attacks that tend to recur or last longer, while still providing the same mechanism of vasoconstriction and pain relief.

Migard should be stored at room temperature, below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Migard is taken orally, usually as a single tablet at the first sign of a migraine attack. The tablet should be swallowed whole with water and not crushed or chewed. If the migraine recurs, a second dose may be considered after a minimum interval as advised by a physician.

The most serious risks include coronary vasospasm, which can cause chest pain or heart attack, and serotonin syndrome, a potentially life‑threatening condition that may occur when combined with other serotonergic agents. Patients should seek immediate medical attention if they experience severe chest discomfort or symptoms of serotonin excess.

Migard is contraindicated in patients with a history of ischemic heart disease, uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to frovatriptan or any other triptan. It should also be avoided in individuals currently taking ergot alkaloids or monoamine oxidase inhibitors.